KORU Medical Systems, Inc. · NASDAQ:KRMD

KORU Medical Systems — Investor Presentation (November 2026)

15 slides from KORU Medical Systems's investor presentation, November 2026

  1. Slide 1: Freedom to Live Life Fully

    Slide 1: Freedom to Live Life Fully

    Freedom to Live Life Fully A Global Leader in Large- Volume Subcutaneous Drug Delivery Nasdaq: KRMD Corporate Overview November 2026

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements dis

  3. Slide 3: Our Company

    Slide 3: Our Company

    Our Company We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic More Time For What Matters Most Capitalizing on the ongoing shift from IV hospital settings to subcutaneous therapy in the home and in infusion clinics KORU Freedom Infus

  4. Slide 4: KORU at a Glance

    Slide 4: KORU at a Glance

    Our Company KORU at a Glance FY2025 REVENUES $41.1M 75% Domestic Core International Core FREEDOM INTEGRATED INFUSION SYSTEM Pharma Services & Clinical Trials ~60k Global Patients DRUG CLEARANCES / REGISTRATIONS Pharma Services and Domestic & 9 Drugs / 30+ Countries Clinical Trials International Core

  5. Slide 5: KORU's Freedom Infusion System

    Slide 5: KORU's Freedom Infusion System

    Our Company KORU’s Freedom Infusion System Mechanical Pumps ~20% of revenues Customizable Consumables ~80% of revenues Simple, Easy-to-use, 97% Patient Customizable Reusable mechanical adherence rate1 platform for use with pump large-volume SC drugs 1. Rutland B, Bosshard J, Southworth C. Enhancing

  6. Slide 6: Global Ig Business Drives Annual Recurring Revenue Base

    Slide 6: Global Ig Business Drives Annual Recurring Revenue Base

    Our Ig Franchise Global Ig Business Drives Annual Recurring Revenue Base Global Patient Base Current 510(k) Clearances Patients using the KORU Freedom 7 SCIg drugs from 4 major Infusion System today pharmaceutical manufacturers cleared represent 2.7M+ annual recurring for use on the KORU Freedom Inf

  7. Slide 7: Movement of Healthcare from Hospital to the Home Driving Subcutaneous Opportunity

    Slide 7: Movement of Healthcare from Hospital to the Home Driving Subcutaneous Opportunity

    Our Opportunity The Movement of Healthcare from Hospital to the Home Driving Large and Growing Subcutaneous Infusion Opportunity Large-Volume Subcutaneous >10ml Infusion SCIg Opportunity Non-Ig Opportunity2 Growing market with <20% SCIg 95+ New Drugs in penetration (vs IVIg) Development >10 mL 1 7 l

  8. Slide 8: Shift from IV to SC Driving a Sizeable and Growing LVSC Market

    Slide 8: Shift from IV to SC Driving a Sizeable and Growing LVSC Market

    Our Opportunity Shift from IV to SC is Driving a Sizeable and Growing Market of Large- Volume Subcutaneous (LVSC) Opportunities Oncology Infusion Pump & Consumables ~$138M 20301 TAM 2 ~$60M 20251 TAM Dosing mL 1 Between 2020-2026, 13 drugs have launched, and the LVSC market has diversified, primaril

  9. Slide 9: Pipeline Opportunities in SCIg and New Drug Therapies

    Slide 9: Pipeline Opportunities in SCIg and New Drug Therapies

    Enabling New Drugs Pipeline Opportunities in SCIg and New Drug Therapies 8 in Pipeline 9 on Label Active Opportunities for New Drugs and Indications 1 Drugs on KORU’s Freedom Infusion System’s Label Commercial Annual Global SCIg 5.4M3 Annual Infusions Drug Asset Infusions Estimate3 Estimated Deferox

  10. Slide 10: Financial Highlights

    Slide 10: Financial Highlights

    Financials Financial Highlights YTD 2026 YTD 2025 Y/Y Δ $48M - $48.5M1 $50.0 Revenue $35.4M $30.2M +17% Growth ≈ 19% CAGR (2023-2026) $40.0 Gross Margin 64.0% 62.1% +190bps 13% CAGR OpEx as % Sales 64.1% 70.2% 620 bps improvement $30.0 (2016-2023) 22% Net Loss ($0.3M) ($2.2M) 84% Improvement $20.0 $

  11. Slide 11: Strategically Positioned for Accelerated Growth

    Slide 11: Strategically Positioned for Accelerated Growth

    Outlook Strategically Positioned for Accelerated Long Term Growth Financial Goals3 Recent Accomplishments1 Strong Fundamentals, $100M revenue Significant Opportunity 1 17% YTD revenue Large and growing market growth over prior year Accelerated for SC drug delivery; ~95 double-digit >10mL drugs in de

  12. Slide 12: Sustained Pathway to +20% Growth CAGR

    Slide 12: Sustained Pathway to +20% Growth CAGR

    Outlook Sustained Pathway to +20% Growth Key Growth Drivers +20% New CAGR indications Sustained SCIg market growth International 8-10% annual growth expansion New product innovation & New product launches & innovation share gain Freedom360 TM, Connectivity and 2nd generation consumables $48-$48.5M1

  13. Slide 13: Execution Milestones on Path to Accelerated Revenue Growth

    Slide 13: Execution Milestones on Path to Accelerated Revenue Growth

    Outlook Execution Milestones on Path to Accelerated Revenue Growth Raising 2026 Financial Guidance • 17-18% revenue growth • Positive Adjusted EBITDA, Cash of >$8M • Gross margin 63-64% Enable More Drugs, Reach More Patients • Add 4 new pipeline collaborations for FY26: 2 of 4 complete • Deferoxamin

  14. Slide 14: Appendix

    Slide 14: Appendix

    Appendix

  15. Slide 15: Non-GAAP Financial Measures

    Slide 15: Non-GAAP Financial Measures

    Non-GAAP Financial Measures This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by othe

Source: company website

More decks from KORU Medical Systems, Inc.

All 20 KORU Medical Systems decks